NeuroSense Therapeutics Ltd. Additional Paid in Capital, Common Stock
NeuroSense Therapeutics Ltd. (NRSN) had Additional Paid in Capital, Common Stock of $46.23 million as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-03-31
- 2025-12-31: Additional Paid in Capital, Common Stock $46.23M.
- 2025-06-30: Additional Paid in Capital, Common Stock $40.85M.
- 2024-12-31: Additional Paid in Capital, Common Stock $39.24M.
- 2024-06-30: Additional Paid in Capital, Common Stock $30.68M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2025-12-31 | $46.23M 20-F · filed 2026-03-31 |
| 2025-06-30 | $40.85M 6-K · filed 2025-08-01 |
| 2024-12-31 | $39.24M 20-F · filed 2026-03-31 |
| 2024-06-30 | $30.68M 6-K · filed 2024-09-30 |
| 2023-12-31 | $24.36M 20-F · filed 2025-04-07 |
| 2022-12-31 | $21.86M 6-K · filed 2024-06-17 |